Multiethnic Investigation of Risk and Immune Determinants of COVID-19 Outcomes.

Autor:	Jun T; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Mathew D; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States., Sharma N; University of California, Santa Barbara, Santa Barbara, CA, United States., Nirenberg S; Scientific Computing, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Huang HH; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Kovatch P; Scientific Computing, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Wherry EJ; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States., Huang KL; Department of Genetics and Genomic Sciences, Center for Transformative Disease Modeling, Tisch Cancer Institute, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2022 Jul 22; Vol. 12, pp. 933190. Date of Electronic Publication: 2022 Jul 22 (Print Publication: 2022).
DOI:	10.3389/fcimb.2022.933190
Abstrakt:	Background: Disparate COVID-19 outcomes have been observed between Hispanic, non-Hispanic Black, and White patients. The underlying causes for these disparities are not fully understood. Methods: This was a retrospective study utilizing electronic medical record data from five hospitals within a single academic health system based in New York City. Multivariable logistic regression models were used to identify demographic, clinical, and lab values associated with in-hospital mortality. Results: A total of 3,086 adult patients with self-reported race/ethnicity information presenting to the emergency department and hospitalized with COVID-19 up to April 13, 2020, were included in this study. While older age (multivariable odds ratio (OR) 1.06, 95% CI 1.05-1.07) and baseline hypoxia (multivariable OR 2.71, 95% CI 2.17-3.36) were associated with increased mortality overall and across all races/ethnicities, non-Hispanic Black (median age 67, interquartile range (IQR) 58-76) and Hispanic (median age 63, IQR 50-74) patients were younger and had different comorbidity profiles as compared to non-Hispanic White patients (median age 73, IQR 62-84; p < 0.05 for both comparisons). Among inflammatory markers associated with COVID-19 mortality, there was a significant interaction between the non-Hispanic Black population and interleukin-1-beta (interaction p-value 0.04). Conclusions: This analysis of a multiethnic cohort highlights the need for inclusion and consideration of diverse populations in ongoing COVID-19 trials targeting inflammatory cytokines. Competing Interests: EW has consulting agreements with and/or is on the scientific advisory board for Merck, Elstar, Janssen, Jounce, Related Sciences, Synthekine, and Surface Oncology. EW is a founder of Surface Oncology and Arsenal Biosciences. EW has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. TJ is employed by and owns stock in Sema4. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Jun, Mathew, Sharma, Nirenberg, Huang, Kovatch, Wherry and Huang.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu